Rethinking Acute SVT Management Podcast-Rethinking Acute SVT Management Video

Rethinking Acute SVT Management Video

Video Transcription

Video Summary

Dr. Kamala Thamarisa discusses atripamil, a short-acting intranasal L-type calcium-channel blocker being studied for patient-managed acute SVT. The described dose is 70 mg total, split between nostrils, with one repeat after 10 minutes if needed (maximum 140 mg in 24 hours). Study results showed SVT termination in about 70% of patients compared with placebo. Reported side effects were generally mild nasal congestion, discomfort, and bleeding. It should be avoided in pre-excited atrial fibrillation, significant bradycardia, sinus-node dysfunction, and high-grade AV block; it is not approved during pregnancy. Other pregnancy options include adenosine, metoprolol, and verapamil.

Keywords

atripamil

acute SVT

intranasal calcium-channel blocker

SVT termination

pregnancy contraindications